Literature DB >> 9462563

Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients.

H Seggewiss1, U Gleichmann, L Faber, D Fassbender, H K Schmidt, S Strick.   

Abstract

OBJECTIVES: We report the acute results and midterm clinical course after percutaneous transluminal septal myocardial ablation (PTSMA) in symptomatic patients with hypertrophic obstructive cardiomyopathy (HOCM).
BACKGROUND: In the treatment of HOCM, surgical myectomy and DDD pacemaker therapy are considered the standard procedural extensions to drug therapy with negatively inotropic drugs. As an alternative nonsurgical procedure for reducing the left ventricular outflow tract (LVOT) gradient, PTSMA by alcohol-induced septal branch occlusion was introduced. However, clinical follow-up has not been sufficiently described.
METHODS: In 25 patients (13 women, 12 men; mean [+/- SD] age 54.7 +/- 15.0 years) who were symptomatic despite sufficient drug therapy, 1.4 +/- 0.6 septal branches were occluded with an injection of 4.1 +/- 2.6 ml of alcohol (96%) to ablate the hypertrophied interventricular septum. After 3-months, follow-up results of LVOT gradients and clinical course were determined.
RESULTS: The invasively determined LVOT gradients could be reduced in 22 patients (88%), with a mean reduction from 61.8 +/- 29.8 mm Hg (range 4 to 152) to 19.4 +/- 20.8 mm Hg (range 0 to 74) at rest (p < 0.0001) and from 141.4 +/- 45.3 mm Hg (range 76 to 240) to 61.1 +/- 40.1 mm Hg (range 0 to 135) after extrasystole. All patients had angina pectoris for 24 h. The maximal creatine kinase increase was 780 +/- 436 U/liter (range 305 to 1,810) after 11.1 +/- 6.0 h (range 4 to 24). Thirteen patients (52%) developed a trifascicular block for 5 min to 8 days requiring temporary (n = 8 [32%]) or permanent (DDD) pacemaker implantation (n = 5 [20%]). An 86-year old woman died 8 days after successful intervention of uncontrollable ventricular fibrillation in conjunction with beta-sympathomimetics in chronically obstructive pulmonary disease. The remaining patients were discharged after 11.3 +/- 5.4 days (range 5 to 24), after an uncomplicated hospital course. Clinical and echocardiographic follow-up was achieved in all 24 surviving patients after 3 months. No cardiac complications occurred. Twenty-one patients (88%) showed clinical improvement, with a New York Heart Association functional class of 1.4 +/- 1.1. A further reduction in LVOT gradient was shown in 14 patients (58%).
CONCLUSIONS: PTSMA of HOCM is a promising nonsurgical technique for septal myocardial reduction, with a consecutive reduction in LVOT gradient. Possible complications are trifascicular blocks, requiring permanent pacemaker implantation, and tachycardiac rhythm disturbances. Clinical long-term observations of larger patient series and a comparison with conventional forms of therapy are necessary to determine the conclusive therapeutic significance.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9462563     DOI: 10.1016/s0735-1097(97)00508-1

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  49 in total

1.  Left ventricular opacification during selective intracoronary injection of echocardiographic contrast in patients with hypertrophic cardiomyopathy.

Authors:  P M Elliott; S J Brecker; W J McKenna
Journal:  Heart       Date:  2000-04       Impact factor: 5.994

Review 2.  Current status of alcohol septal ablation for patients with hypertrophic cardiomyopathy.

Authors:  H Seggewiss
Journal:  Curr Cardiol Rep       Date:  2001-03       Impact factor: 2.931

Review 3.  Emerging indications for permanent pacing.

Authors:  D L Wolbrette; G V Naccarelli
Journal:  Curr Cardiol Rep       Date:  2000-07       Impact factor: 2.931

4.  Gated SPECT in patients with hypertrophic obstructive cardiomyopathy undergoing transcoronary ethanol septal ablation.

Authors:  Felix Y j Keng; Su Min Chang; Eduardo Cwajg; Zuo-Xiang He; Nasser M Lakkis; Sherif F Nagueh; William H Spencer; Mario S Verani
Journal:  J Nucl Cardiol       Date:  2002 Nov-Dec       Impact factor: 5.952

5.  Long-term results of apico-aortic valved conduit for severe idiopathic hypertrophic subaortic stenosis.

Authors:  A Renzulli; R Gregorio; M De Feo; G Ismeno; F E Covino; M Cotrufo
Journal:  Tex Heart Inst J       Date:  2000

Review 6.  Pacing for drug-refractory or drug-intolerant hypertrophic cardiomyopathy.

Authors:  Mohammed Qintar; Abdulrahman Morad; Hazem Alhawasli; Khaled Shorbaji; Belal Firwana; Adib Essali; Waleed Kadro
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

7.  Percutaneous myocardial ablation for left mid-ventricular obstructive hypertrophic cardiomyopathy.

Authors:  I Tengiz; E Ercan; U O Türk
Journal:  Int J Cardiovasc Imaging       Date:  2005-12-12       Impact factor: 2.357

8.  Increasing evidence for the safety and efficacy of alcohol septal ablation during medium- and long-term follow-up.

Authors:  M Pauschinger; A Keren
Journal:  Clin Res Cardiol       Date:  2007-11-05       Impact factor: 5.460

9.  One-year follow-up of percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy in 312 patients: predictors of hemodynamic and clinical response.

Authors:  L Faber; D Welge; D Fassbender; H K Schmidt; D Horstkotte; H Seggewiss
Journal:  Clin Res Cardiol       Date:  2007-09-25       Impact factor: 5.460

Review 10.  Management of hypertrophic cardiomyopathy in children.

Authors:  Hubert Seggewiss; Angelos Rigopoulos
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.